ALK — Targeted Therapies, Trials & Pipeline

Anaplastic lymphoma kinase fusions define a targetable subset of NSCLC and other tumors treated with successive generations of ALK TKIs.

Approved drugs targeting ALK

Investigational pipeline agents

Landmark trials